Latest Headlines

  1. SLAS Discovery: Advancing Tools For Cancer Fibrosis And Drug Discovery 7/29/2025

    Volume 34 of SLAS Discovery includes two original research articles, one short communication and one entry in the upcoming Special Issue on EUOS/SLAS Joint Challenge: Compound Solubility.

  2. Making Medicine Out Of Millipedes 7/29/2025

    Millipedes get a bad rap — their many legs put people off and could classify them as “creepy crawly.” But these anthropods’ secretions could hold the key to new drug discovery for the treatment of neurological diseases and pain.

  3. Astrocytes Identified As Hidden Culprit Behind PTSD 7/29/2025

    Did you know that patients with post traumatic stress disorder (PTSD) often struggle to forget traumatic memories, even long after the danger has passed? This failure to extinguish fear memories has long puzzled scientists and posed a major hurdle for treatment, especially since current medications targeting serotonin receptors offer limited relief for only a subset of patients.

  4. GSK And Hengrui Pharma Enter Agreements To Develop Up To 12 Innovative Medicines Across Respiratory, Immunology & Inflammation And Oncology 7/28/2025

    GSK plc today announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 innovative medicines, adding significant new growth opportunities to the company beyond 2031.

  5. LENZ Therapeutics Announces NMPA Submission Of New Drug Application For LNZ100 In China For The Treatment Of Presbyopia 7/28/2025

    LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that CORXEL Pharmaceuticals (“CORXEL”) has submitted the New Drug Application (NDA) for LNZ100 to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People’s Republic of China (PRC).

  6. Kling Bio Announces Collaboration With Sanofi For Accelerated Discovery Of Neutralizing Antibodies 7/24/2025

     Kling Bio ("Kling" or "the Company"), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a collaboration and license option agreement with Sanofi for the discovery of antibodies and epitopes using its groundbreaking B cell immortalization and screening platform, Kling-Select.

  7. Precision BioSciences Receives FDA Orphan Drug Designation For PBGENE-DMD For The Treatment Of Duchenne Muscular Dystrophy 7/23/2025

    Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).

  8. Bavarian Nordic Receives Acceptance From Health Canada For Review Of The New Drug Submission For Its Chikungunya Vaccine 7/22/2025

    Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older.

  9. Introducing Latent-X, A Frontier Generative AI Model For Protein Binder Design Accessible Via No-Code Platform For Push-Button Protein Design 7/22/2025

    Today, Latent Labs is launching Latent-X, a frontier AI model for push button protein design, outperforming competing models under identical laboratory conditions.

  10. Answer ALS Launches AI Drug Development Collaboration With GATC Health, Pennington Biomedical Research Center, And Tulane To Advance ALS Treatment Discovery 7/22/2025

    Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases.